Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

72 results about "Initiation factor" patented technology

Initiation factors are proteins that bind to the small subunit of the ribosome during the initiation of translation, a part of protein biosynthesis. Initiation factors can interact with repressors to slow down or prevent translation or they can interact with activators to help them start or increase the rate of translation. In bacteria they are simply called Ifs (i.e.., IF1, IF2, & IF3) and in eukaryotes they are known as eIFs (i.e.., eIF1, eIF2, eIF3). In eukaryotic transcription these are also called the general transcription factors, or σ factors...

Method and apparatus for preferred customer marketing delivery based on biometric data for a customer

A computer implemented method, apparatus, and computer usable program product for automatically determining a marketing status for a customer. Biometric readings for the customer are received from a set of biometric devices associated with a retail facility to form biometric data describing a set of physiological responses of the customer. The biometric data is analyzed to identify a set of marketing initiation factors that indicate a degree of receptivity of the customer to marketing messages. In response to the set of marketing initiation factors indicating initiation of marketing to the customer, a customized marketing message is generated for the customer. The customized marketing message is transmitted to a display device for display to the customer in real-time as the customer is shopping.
Owner:TERRACE LICENSING LLC

Method for detecting activated blood coagulation factor XI in human intravenous immunoglobulin

ActiveCN103185710AAvoid preactivationIndirectly reflect changes in production contentFluorescence/phosphorescenceInitiation factorFactor ii
The invention discloses a method for detecting an activated blood coagulation factor XI in human intravenous immunoglobulin. The method comprises the steps as follows: (1) mixing an IVIG (intravenous immunoglobulin) sample with specially-preprocessed platelet-poor plasma (PPP); (2) adding a thrombin specific fluorogenic substrate with a phospholipid agent into a reaction system; (3) adding an initiation factor for starting a TGT (thrombin generation test), wherein the initiation factor comprises a calcium ion source and the phospholipid agent; (4) obtaining a thrombin generation curve providing parameters by the optimized reaction system; and (5) negatively correlating the peak time of thrombin (TTP) of the detected sample with the FXIa (activated blood coagulation factor XI) level in the sample. The FXIa level in the detected sample can be indirectly obtained by comparing the TTP of the detected sample with that of an FXIa standard sample. The method is suitable for detecting residual micro FXIa in human intravenous immunoglobulin (IVIG) products and is used for extracorporal evaluation of thrombosis risk of related products.
Owner:BLOOD TRASFUSION INST CHINESE ACAD OF MEDICAL SCI +1

Cell-free system for synthesis of proteins derived from cultured mammalian cells

Prepared is an extract composition having an improved protein synthetic activity in a cell-free protein synthesis system using a mammalian cultured cell extract. An eukaryotic translation initiation factor and / or translational regulator are added to a cell-free protein synthesis system comprising an extract prepared from cultured mammalian cells and a template mRNA. These factors are one or more selected from the group consisting of eukaryotic translation initiation factors 4E (eIF4E), 2 (eIF2) and 2B (eIF2B), and eukaryotic translational regulator p97.
Owner:RIKEN

Use of apoptosis-specific eif-5a sirna to down regulate expression of proinflammatory cytokines to treat sepsis

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for down regulating pro-inflammatory cytokines in a mammal by administering siRNA against eIF-5A1 to the mammal to treat / prevent sepsis and / or hemorrhagic shock.
Owner:SENESCO TECHNOLOGIES INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products